Doctor Dawid Miskowiec

no speaker photo

Speaker

Dawid Miskowiec

Medical University of Lodz, Lodz (Poland)

Specialities : Arrhythmias-General , Acute Coronary Syndromes, Atrial Fibrillation

13 presentations from this speaker

Left atrial diameter as a simple parameter predicting the effectiveness of antazoline-based pharmacological approach to cardioversion of atrial fibrillation

Event : EuroEcho 2018

Session : HIT Poster session 3
Speaker : D Miskowiec (Lodz,PL)

Aortic diameters are dependent on the bicuspid aortic valve phenotype and the degree of aortic stenosis - a systematic review, meta-analysis and meta-regression

Event : ESC Congress 2017

Session : Biomarkers and phenotype in aortic stenosis
Speaker : D Miskowiec (Lodz,PL)

Diabetes as an independent predictor of left ventricular longitudinal strain reduction at rest and during dobutamine stress test in patients with significant coronary artery disease.

Event : ESC Congress 2017

Session : Stable CAD
Speaker : D Miskowiec (Lodz,PL)

Elevated microRNA-499 level in early phase of non-ST elevation acute coronary syndromes predicts increased long-term risk of major adverse cardiac events.

Event : ESC Congress 2017

Session : Acute cardiac care
Speaker : D Miskowiec (Lodz,PL)

Bicuspid aortic valve phenotype and aortic diameter - does it really matter? A systematic review and meta-analysis

Event : ESC Congress 2016

Session : Congenital heart disease imaging
Speaker : D Miskowiec (Lodz,PL)

Free circulating miRNAs (miR1, miR-133a, miR-208a, miR-499) differentiate clinical types of coronary disease: acute myocardial infarction, unstable angina and stable coronary artery disease

Event : ESC Congress 2016

Session : Blood markers in acute coronary syndrome
Speaker : D Miskowiec (Lodz,PL)

MiR-1, miR-133a and miR-499 plasma levels correlate with cardiac necrosis markers and reflect the impaired left ventricular systolic function in early phase of acute coronary syndromes

Event : Acute Cardiovascular Care 2016

Session : Acute coronary syndrome - Non ST-elevation myocardial infarction
Speaker : D Miskowiec (Lodz,PL)

The assessment of feasibility of conscious sedation for transcatheter implantation of atrial septal occluders with the real-time transoesophageal echocardiography guidance

Event : ESC Congress 2016

Session : Echocardiography Valvular / Perioperative
Speaker : D Miskowiec (Lodz,PL)

The cardiac-enriched miRNAs plasma levels (miR-1, miR-133a, miR-499) reflect the impaired left ventricular systolic function and correlate with cardiac necrosis markers in early phase of NSTE-ACS

Event : EuroEcho 2016

Session : HIT Poster session 2
Speaker : D Miskowiec (Lodz,PL)

Transesophageal echocardigoraphy under conscious sedation for guiding cryoballoon pulmonary vein isolation in paroxysmal atrial fibrillation - the safety and feasibility study

Event : EuroEcho 2016

Session : HIT Poster session 2
Speaker : D Miskowiec (Lodz,PL)

Bicuspid aortic valve morphology and its impact on aortic diameter - a meta-analysis

Event : EuroEcho 2015

Session : HIT Poster session 3
Speaker : D Miskowiec (Lodz,PL)

Echocardiographic assessment of regional left atrial longitudinal strain by tissue Doppler and speckle tracking method - a comparison study

Event : EuroEcho 2015

Session : HIT Poster session 3
Speaker : D Miskowiec (Lodz,PL)

Left atrial dysfunction assessed by two dimensional speckle tracking echocardiography in patients with impaired left ventricular ejection fraction and sleep-disordered breathing

Event : EuroEcho 2015

Session : HIT Moderated Poster session: imaging in everyday practice
Speaker : D Miskowiec (Lodz,PL)

Members get more

1ESC Professional Members – access all resources from general ESC events
2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
3Under 40 or in training - with a Combined Membership, access all resources

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

Our mission: To reduce the burden of cardiovascular disease